Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.62 - $2.71 $37,324 - $62,438
-23,040 Reduced 47.03%
25,953 $49.3 Million
Q1 2024

May 15, 2024

BUY
$2.71 - $19.57 $132,771 - $958,793
48,993 New
48,993 $139 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $229M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Point72 (Difc) LTD Portfolio

Follow Point72 (Difc) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 (Difc) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 (Difc) LTD with notifications on news.